2016. A phase III, randomized, non-inferiority study comparing the efficacy and safety of biosimilar filgrastim versus originator filgrastim for chemotherapy-induced neutropenia in breast cancer patients . Clinics. 71, 10 (Oct. 2016), 586–592. DOI:https://doi.org/10.6061/clinics/2016(10)06.